1. Home
  2. BZAI vs SABS Comparison

BZAI vs SABS Comparison

Compare BZAI & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blaize Holdings Inc.

BZAI

Blaize Holdings Inc.

HOLD

Current Price

$2.42

Market Cap

246.7M

Sector

N/A

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.75

Market Cap

201.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BZAI
SABS
Founded
2010
2014
Country
United States
United States
Employees
254
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
246.7M
201.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BZAI
SABS
Price
$2.42
$3.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$4.67
$10.75
AVG Volume (30 Days)
9.2M
380.8K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$239.02
N/A
Revenue Next Year
$45.85
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$1.60
52 Week High
$6.76
$6.60

Technical Indicators

Market Signals
Indicator
BZAI
SABS
Relative Strength Index (RSI) 62.43 47.35
Support Level $2.12 $3.55
Resistance Level $2.45 $4.11
Average True Range (ATR) 0.27 0.24
MACD -0.01 -0.02
Stochastic Oscillator 65.97 38.81

Price Performance

Historical Comparison
BZAI
SABS

About BZAI Blaize Holdings Inc.

Blaize Holdings Inc provides transformative artificial intelligence (AI)-enabled edge computing solutions comprised of both its proprietary hardware and software, and third-party hardware solutions. Its portfolio includes programmable AI processors in various form factors, which can be deployed across sectors such as smart cities, defense, retail, and enterprise markets. The company operates as a single operating and reportable segment. The majority of the company's revenue is derived from Hardware revenue, which includes the sale of its semiconductor products and/or third-party hardware products that support semiconductor products through various supply agreements. Geographically, it generates the maximum revenue from China.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: